Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="181964.fig.002a" src="https://static.hindawi.com/articles/au/volume-2012/181964/figures/181964.fig.002a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>EGFR for bladder cancer death</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="181964.fig.002b" src="https://static.hindawi.com/articles/au/volume-2012/181964/figures/181964.fig.002b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>ErbB2 for bladder cancer death</td></tr></table></td></tr></table>

<table>Forest plots of prognostic significance of EGFR and ErbB2 overexpression on bladder cancer death. (a) EGFR. (b) ErbB2. Hazard ratios and 95% (confidence intervals) CIs for patients with either EGFR- or ErbB2-positive tumors.</table>

Advances in Urology

fig2

Figure 2

Figure 2: Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis 